Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.

Lund LH, Benson L, Dahlstr├Âm U, Edner M.

JAMA. 2012 Nov 28;308(20):2108-17. doi: 10.1001/jama.2012.14785.

PMID:
23188027
2.

Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction.

Agarwal V, Briasoulis A, Messerli FH.

Heart Fail Rev. 2013 Jul;18(4):429-37. doi: 10.1007/s10741-012-9329-8. Review.

PMID:
22678768
3.

Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction.

Driscoll A, Currey J, Tonkin A, Krum H.

Cochrane Database Syst Rev. 2015 Dec 21;(12):CD009889. doi: 10.1002/14651858.CD009889.pub2. Review.

PMID:
26689943
4.

Renin-angiotensin-aldosterone system inhibitors in heart failure.

Shearer F, Lang CC, Struthers AD.

Clin Pharmacol Ther. 2013 Oct;94(4):459-67. doi: 10.1038/clpt.2013.135. Epub 2013 Jul 12. Review.

PMID:
23852393
5.

Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.

Beldhuis IE, Streng KW, Ter Maaten JM, Voors AA, van der Meer P, Rossignol P, McMurray JJ, Damman K.

Circ Heart Fail. 2017 Feb;10(2). pii: e003588. doi: 10.1161/CIRCHEARTFAILURE.116.003588. Review.

PMID:
28209765
6.
7.
8.

Modulation of the renin-angiotensin-aldosterone system in heart failure.

George J, Struthers AD, Lang CC.

Curr Atheroscler Rep. 2014 Apr;16(4):403. doi: 10.1007/s11883-014-0403-7. Review.

PMID:
24510580
9.

Heart failure with preserved ejection fraction: a clinical dilemma.

Komajda M, Lam CS.

Eur Heart J. 2014 Apr;35(16):1022-32. doi: 10.1093/eurheartj/ehu067. Epub 2014 Mar 11. Review.

PMID:
24618346
10.

Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.

Meune C, Wahbi K, Duboc D, Weber S.

J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):368-75. doi: 10.1177/1074248410391667. Epub 2010 Dec 30. Review.

PMID:
21193681
11.

Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction.

Konstantinou DM, Chatzizisis YS, Giannoglou GD.

Pharmacol Ther. 2013 Nov;140(2):156-66. doi: 10.1016/j.pharmthera.2013.05.012. Epub 2013 Jun 19. Review.

PMID:
23792088
12.

Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies.

Fukuta H, Goto T, Wakami K, Ohte N.

Heart Fail Rev. 2017 Jul 12. doi: 10.1007/s10741-017-9637-0. [Epub ahead of print] Review.

PMID:
28702858
13.

╬▓-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration.

Yamamoto K.

J Cardiol. 2015 Sep;66(3):189-94. doi: 10.1016/j.jjcc.2015.02.004. Epub 2015 Apr 13. Review.

14.

Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.

Valluri A, Struthers AD, Lang CC.

Curr Heart Fail Rep. 2014 Mar;11(1):31-9. Review.

PMID:
24234398
15.

Angiotensin receptor blockers for heart failure.

Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003040. doi: 10.1002/14651858.CD003040.pub2. Review.

PMID:
22513909
16.

The renin-angiotensin-aldosterone system and heart failure.

Sayer G, Bhat G.

Cardiol Clin. 2014 Feb;32(1):21-32, vii. doi: 10.1016/j.ccl.2013.09.002. Review.

PMID:
24286576
17.

Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.

Rossignol P, Zannad F, Pitt B; Writing group of 10th Global Cardio Vascular Clinical Trialist forum held on December 6th-7th 2013 in Paris, France.

Int J Cardiol. 2014 Dec 20;177(3):731-3. doi: 10.1016/j.ijcard.2014.11.004. Epub 2014 Nov 5. Review.

PMID:
25465821
18.

Heart failure with preserved ejection fraction: pathophysiology and emerging therapies.

From AM, Borlaug BA.

Cardiovasc Ther. 2011 Aug;29(4):e6-21. doi: 10.1111/j.1755-5922.2010.00133.x. Epub 2010 Mar 29. Review.

PMID:
20370792
19.

Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction.

Tannenbaum S, Sayer GT.

Curr Opin Cardiol. 2015 May;30(3):250-8. doi: 10.1097/HCO.0000000000000163. Review.

20.

Targeting the renin-angiotensin-aldosterone system in heart failure.

Lang CC, Struthers AD.

Nat Rev Cardiol. 2013 Mar;10(3):125-34. doi: 10.1038/nrcardio.2012.196. Epub 2013 Jan 15. Review.

PMID:
23319100

Supplemental Content

Support Center